CHA Bio Group｜차바이오그룹

CHA Bio Group is a leading force in biotechnology research, dedicated to creating future value in the bio and healthcare industry through its innovative BIO Eco System. With a commitment to exceeding initial achievements and reaching the pinnacle of excellence, CHA Bio Group operates with a unique ecosystem that integrates academic, research, medical networks, and bio-industry business.

CHA Bio Group excels in developing advanced biopharmaceuticals, including cell and gene therapy products, next-generation vaccines, and targeted anticancer drugs. This is powered by world-class R&D capabilities, including the world's largest cell library and an independently developed vaccine adjuvant platform. The company's primary address is 335, pangyo-ro, CHA Bio Complex, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, KR.

CHA Bio Group maximizes its business potential through the vertical integration of its subsidiaries, including CHA Biotech, CMG Pharmaceutical, and CHA Vaccine Institute, along with CHA Healthcare, CHA Meditech, CHA Bio F&C, CHA Carees, Seoul CRO, and Solidus Investment. CHA Bio Group continues to innovate, expanding its CGT CDMO business through Matica Biotechnology in the United States and leading medical advances in the US, Australia, Japan, and Southeast Asia via the Hollywood CHA Hospital in LA. We invite the manager of CHA Bio Group to create a customized and exclusive company showcase and product listing on our platform.